TB-500 Dosage Guide: Loading, Maintenance, and Reconstitution Protocols

TB-500 Dosage Guide: Loading, Maintenance, and Reconstitution Protocols

TB-500 is the synthetic form of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide found in virtually every cell and tissue of the human body. It plays essential roles in cell proliferation, migration, differentiation, and angiogenesis. In the context of tissue repair, TB-500's most notable function is its ability to upregulate actin polymerization — the cytoskeletal process that enables cells to move, divide, and form new tissue structures.

TB-500 is primarily used for injury recovery, particularly for chronic musculoskeletal injuries that have been slow to heal. When combined with BPC-157, it forms one of the most potent peptide healing protocols available.

How TB-500 Works

TB-500 promotes tissue healing through several mechanisms:

• Actin sequestration: Binds G-actin to reduce free actin, which paradoxically promotes actin dynamics and cell mobility
• Angiogenesis: Stimulates formation of new blood vessels to supply healing tissue
• Cell migration: Promotes migration of keratinocytes, endothelial cells, and fibroblasts into the wound zone
• Anti-inflammatory: Reduces inflammatory cytokines and modulates immune cell activity in injured tissue
• Satellite cell activation: Encourages muscle stem cell activity for muscle repair

Unlike BPC-157, which has stronger local tissue effects, TB-500 is considered more systemically distributed — it travels throughout the body and supports healing at multiple sites simultaneously.

TB-500 Dosage: Loading Phase

The standard TB-500 protocol uses a two-phase approach: a loading phase with higher doses to establish therapeutic tissue levels, followed by a maintenance phase.

Standard loading phase:

• Dose: 2–2.5 mg per injection
• Frequency: 2 injections per week
• Duration: 4–6 weeks

Total weekly loading dose: 4–5 mg per week

Body weight-adjusted dosing: Some practitioners adjust dose based on body weight at approximately 2.0–2.5 mg per injection regardless of weight, as the published data does not strongly support proportional scaling for therapeutic effects in humans.

Example loading protocol:

• Monday: 2.5 mg subcutaneous injection
• Thursday: 2.5 mg subcutaneous injection
• Repeat for 4–6 weeks

TB-500 Dosage: Maintenance Phase

After the loading phase, many practitioners transition to a reduced maintenance dose to sustain tissue repair benefits while reducing total peptide consumption.

Standard maintenance phase:

• Dose: 2 mg per injection
• Frequency: 2 injections per month (every 2 weeks)
• Duration: Ongoing, typically 2–4 months post-loading

Maintenance rationale: By the end of the loading phase, tissue levels are established. Lower maintenance doses are sufficient to maintain signaling and continue healing.

Example maintenance schedule:

• 1st of month: 2 mg injection
• 15th of month: 2 mg injection
• Repeat for 2–4 months

Some users who have achieved full recovery from their injury discontinue TB-500 entirely after the loading phase. Maintenance dosing is most useful for chronic conditions or prevention of recurrence.

Acute Injury Protocol

For a specific acute injury (muscle strain, ligament sprain, tendon tear), a targeted loading protocol is often used:

Week 1–2 (acute phase):

• 2.5 mg 3x per week (Monday, Wednesday, Friday)
• Total: 7.5 mg/week

Week 3–6 (recovery phase):

• 2.5 mg 2x per week
• Total: 5 mg/week

Week 7–10 (maintenance):

• 2 mg 1x per week

This more aggressive front-loading for acute injuries is based on the rationale that getting TB-500 to injured tissue quickly during the inflammatory and proliferative phases of healing (days 1–21) is most critical.

TB-500 vs. BPC-157: Key Differences

Both peptides promote tissue healing, but their mechanisms and optimal applications differ:

| Feature | TB-500 | BPC-157 | |---|---|---| | Primary mechanism | Actin dynamics, cell migration | GH receptor upregulation, nitric oxide | | Best for | Systemic healing, chronic injuries | Local tissue repair, gut healing | | Administration | SubQ anywhere | SubQ near injury preferred | | Gut effects | Limited | Strong | | Half-life | Hours to days | Hours | | Synergy | Yes, stacks well with BPC-157 | Yes, stacks well with TB-500 |

The Healing Stack: TB-500 + BPC-157

Combining TB-500 and BPC-157 produces synergistic tissue repair effects that exceed either peptide used alone. This combination is widely used for:

• Tendon and ligament injuries
• Muscle tears
• Post-surgical recovery
• Chronic musculoskeletal pain
• Joint injuries

Combined loading protocol:

• BPC-157: 250–500 mcg 2x daily (SubQ or IM)
• TB-500: 2–2.5 mg 2x weekly (SubQ)
• Duration: 4–8 weeks

The peptides can be injected separately or, if both are water-reconstituted, combined in the same syringe for convenience.

Reconstitution

TB-500 is sold as lyophilized (freeze-dried) powder and requires reconstitution with bacteriostatic water before injection.

Step-by-step reconstitution:

1. Allow the peptide vial to come to room temperature (5 minutes)
2. Draw the appropriate volume of bacteriostatic water (BAC water) into a syringe
3. Insert the needle into the TB-500 vial at an angle
4. Slowly release the BAC water down the side of the vial — do not inject directly onto the powder (creates bubbles)
5. Gently swirl the vial to dissolve; do not shake vigorously
6. The solution should be clear or slightly opalescent

Common concentration calculations:

For a 5 mg vial:

• Add 2.5 mL BAC water = 2 mg/mL (each 0.1 mL = 200 mcg)
• Add 5 mL BAC water = 1 mg/mL (each 0.1 mL = 100 mcg)

For a 2 mg vial:

• Add 2 mL BAC water = 1 mg/mL (each 0.1 mL = 100 mcg)
• For a 2 mg dose, draw 2 mL

Recommended concentration for ease of dosing: 2 mg/mL in a 5 mg vial (add 2.5 mL BAC water). A 2.5 mg dose = 1.25 mL (12.5 on a U-100 insulin syringe).

Storage

Lyophilized powder:

• Store at 2–8°C (refrigerator) — stable for 12–24 months
• Can be stored at -20°C for longer term
• Keep away from light

Reconstituted solution:

• Store at 2–8°C
• Use within 28–30 days
• Do not freeze reconstituted solution
• Discard if solution is cloudy, contains particles, or has changed color

Administration

TB-500 is almost exclusively administered subcutaneously (SubQ).

Injection sites: Abdomen (most common), thigh, upper arm Needle: 27–30 gauge, 0.5 inch insulin syringe Technique: Pinch skin fold, 45-degree angle, slow injection Rotation: Rotate injection sites between doses to prevent lipohypertrophy

Unlike BPC-157, TB-500 does not need to be injected near the injured area. Its systemic distribution means injection anywhere (typically the abdomen for convenience) produces bodywide therapeutic effects.

Cycling and Duration

For acute injuries:

• Use for the duration of healing (typically 6–12 weeks total)
• Discontinue when healed; no formal cycling required

For chronic conditions or performance:

• 8–12 week on-cycle
• 4–6 weeks off
• Reassess and repeat as needed

There is no evidence of significant receptor downregulation or suppression of endogenous Thymosin Beta-4 production with exogenous TB-500. Nonetheless, cycling remains sensible given the absence of long-term human safety data.

Side Effects and Safety

TB-500 has a favorable safety profile based on available animal data and self-reported human use:

Commonly reported (mild):

• Fatigue or "lethargy" in the first few days of use
• Mild flu-like symptoms at high loading doses
• Injection site redness or mild swelling
• Transient headache

Theoretical concerns:

• Cancer risk: Like BPC-157, TB-500 promotes angiogenesis and cell proliferation. While this supports healing in healthy tissue, the theoretical concern exists about potential tumor promotion in individuals with pre-existing malignancy. TB-500 should not be used by individuals with active cancer.
• Autoimmune conditions: Given TB-500's immune-modulating role, individuals with autoimmune diseases should consult a physician before use.

At standard dosing (2–5 mg/week), reported side effects are generally mild and transient.

Frequently Asked Questions

Q: How long does TB-500 take to work? Most users with acute injuries notice improved pain and mobility within 1–3 weeks of starting the loading phase. Chronic or severe injuries may require 4–8 weeks before significant improvement is apparent. Full tendon or ligament healing still requires the natural remodeling timeline (months), but TB-500 appears to accelerate this process meaningfully.

Q: Can I inject TB-500 every day? Daily injection is generally unnecessary and not standard practice. The 2x weekly loading schedule maintains therapeutic tissue levels. Some practitioners use every-other-day injection for severe injuries in early recovery, but this is an aggressive protocol without strong supporting evidence.

Q: Do I need to refrigerate TB-500 after mixing? Yes. Once reconstituted with bacteriostatic water, TB-500 must be refrigerated and used within 28–30 days. Never leave reconstituted peptides at room temperature for extended periods.

Q: Can TB-500 heal old injuries? TB-500 may provide benefit even for longstanding injuries by stimulating vascular ingrowth and cell migration into chronically avascular tissue (e.g., tendon midportion). However, response is typically more modest compared to acute injury use. Combination with BPC-157 and physical therapy is recommended for chronic injuries.

Q: Is TB-500 the same as Thymosin Beta-4? TB-500 is a peptide derived from the active region of Thymosin Beta-4 — specifically the actin-binding domain (amino acids 17–23). It is not the full 43-amino acid protein. This truncated fragment retains most of Thymosin Beta-4's healing properties and is more practical to synthesize and administer.

Q: Can I stack TB-500 with GH peptides like ipamorelin? Yes. Some practitioners run TB-500 alongside a GH secretagogue stack for combined tissue repair and body composition benefits. The two are complementary: GH peptides support systemic anabolism and recovery, while TB-500 addresses specific tissue repair mechanisms.

---

This article is for informational purposes only. TB-500 is not FDA-approved for human therapeutic use. Consult a healthcare provider before beginning any peptide protocol.